Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by BostonGene
< Previous
1
2
Next >
BostonGene to Present 13 Abstracts at the American Association for Cancer Research Annual Meeting 2026 Showcasing AI-Platform for Drug Development
April 09, 2026
From
BostonGene
Via
Business Wire
BostonGene to Highlight the Role of AI Foundation Models in Optimizing Cancer Immunotherapy at Precision Medicine World Conference 2026
March 02, 2026
From
BostonGene
Via
Business Wire
BostonGene Named “Overall Immunology Company of the Year” by BioTech Breakthrough for Its AI-Driven Platform That Transforms Immuno-Oncology Drug Development Through Advanced Biomarker Discovery, Real-Time Monitoring, and Precision Patient Selection
December 16, 2025
From
BostonGene
Via
Business Wire
BostonGene to Present Seven Studies Unveiling Novel AI-Driven Breast Cancer Breakthroughs at SABCS 2025
December 08, 2025
From
BostonGene
Via
Business Wire
BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition
November 25, 2025
From
BostonGene
Via
Business Wire
BostonGene and Kyoto University Partner to Accelerate Precision Drug Development
November 12, 2025
From
BostonGene
Via
Business Wire
BostonGene to Present Omnimodal Foundation AI for Cancer and the Immune System at SITC 2025 Annual Meeting
October 28, 2025
From
BostonGene
Via
Business Wire
BostonGene to Highlight Omnimodal AI Innovations for Precision Oncology at the 21st Annual Precision Oncology & RadMed Symposium
October 23, 2025
From
BostonGene
Via
Business Wire
BostonGene Honored with Five 2025 Stevie® Awards for Technology Excellence
October 21, 2025
From
BostonGene
Via
Business Wire
BostonGene Showcases AI-Powered Multimodal Analytics at ESMO Congress 2025 to Advance Cancer Research and Drug Development
October 14, 2025
From
BostonGene
Via
Business Wire
BostonGene Named Platinum Winner for AI Research Innovation at 2025 Pinnacle Awards
September 17, 2025
From
BostonGene
Via
Business Wire
BostonGene to Participate in the 2025 IASLC World Conference on Lung Cancer
August 26, 2025
From
BostonGene
Via
Business Wire
BostonGene Publishes Landmark Study Providing Clinical and Analytical Validation for Its Multimodal RNA and DNA Assay
August 12, 2025
From
BostonGene
Via
Business Wire
BostonGene Named “AI-based Drug Discovery Solution of the Year” in 2025 AI Breakthrough Awards Program
August 07, 2025
From
BostonGene
Via
Business Wire
BostonGene Announces Collaboration with SWOG Cancer Research Network to Drive Personalized Approaches
July 08, 2025
From
BostonGene
Via
Business Wire
BostonGene to Present AI-Powered Solutions Advancing Patient-Centric Drug Development at The Festival of Genomics & Biodata Boston 2025
June 18, 2025
From
BostonGene
Via
Business Wire
BostonGene’s Multiomic AI Platform Uncovers Therapeutic Targets in Invasive Lobular Carcinoma, Wins GRASP Advocate Choice Award at ASCO 2025
June 09, 2025
From
BostonGene
Via
Business Wire
BostonGene Announces Participation at the American Association for Cancer Research Annual Meeting 2025
April 21, 2025
From
BostonGene
Via
Business Wire
BostonGene Appoints Dr. Ferran Prat as Chief Commercial Officer
April 08, 2025
From
BostonGene
Via
Business Wire
BostonGene to Participate in the 114th Annual Meeting of the United States and Canadian Academy of Pathology
March 24, 2025
From
BostonGene
Via
Business Wire
BostonGene Named a Fierce Life Sciences Innovation Awards Winner in the AI Innovation Category
March 13, 2025
From
BostonGene
Via
Business Wire
BostonGene Collaborates with BeiGene to Advance Biomarker Discovery in Mantle Cell Lymphoma
February 11, 2025
From
BostonGene
Via
Business Wire
BostonGene Contributes to Friends of Cancer Research White Paper Introducing a Novel Process for Companion Diagnostics for Rare Biomarkers and Indications
February 04, 2025
From
BostonGene
Via
Business Wire
BostonGene Evaluates Novel Therapies and Immune System Profiling as a Marker of Response in Patients with Gastrointestinal Cancers
January 14, 2025
From
BostonGene
Via
Business Wire
BostonGene Unveils Transformative Breast Cancer Research at 2024 San Antonio Breast Cancer Symposium, Showcasing Precision Tools for Tailored Treatment Approaches
December 10, 2024
From
BostonGene
Via
Business Wire
BostonGene Announces Twelve Abstracts Selected for Presentation at the 66th American Society of Hematology Annual Meeting & Exposition
December 06, 2024
From
BostonGene
Via
Business Wire
BostonGene to Showcase AI-Driven Molecular Profiling Solutions at the Association for Molecular Pathology 2024 Annual Meeting
November 21, 2024
From
BostonGene
Via
Business Wire
GlobalData Honors BostonGene with Five Awards in the 2024 Pharmaceutical Technology Excellence Awards
November 12, 2024
From
BostonGene
Via
Business Wire
BostonGene to Present Research with Leading Cancer Centers at Society for Immunotherapy of Cancer’s Annual Meeting
November 06, 2024
From
BostonGene
Via
Business Wire
BostonGene to Participate in Pathology Visions 2024, Driving Collaborative Advancements in Digital Pathology and Regulatory Science
November 01, 2024
From
BostonGene
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.